Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AIMD Ainos	$3.82 -4.0%	$3.04	$2.00 ▼ $5.00	$18.54M	2.2	7.18 million shs	63,597 shs
ATNF 180 Life Sciences	$2.87 -3.7%	$3.02	$0.66 ▼ $17.75	$17.33M	0.38	22.03 million shs	7.91 million shs
IXHL Incannex Healthcare	$0.66 +6.6%	$0.49	$0.08 ▼ $3.12	$18.19M	7.67	147.08 million shs	83.22 million shs
VIVS VivoSim Labs	$2.44 +30.5%	$1.84	$1.41 ▼ $21.96	$4.86M	0.94	29,499 shs	12.77 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AIMD Ainos	-4.02%	+7.30%	+46.36%	+13.22%	+21.02%
ATNF 180 Life Sciences	-3.69%	-40.33%	-18.47%	+181.37%	+47.94%
IXHL Incannex Healthcare	+6.63%	+12.07%	-25.11%	+225.91%	-62.56%
VIVS VivoSim Labs	+30.48%	+15.64%	+21.39%	+40.63%	+243,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AIMD Ainos	1.0318 of 5 stars	0.0	3.0	0.0	0.0	4.3	1.7	0.0
ATNF 180 Life Sciences	0.9723 of 5 stars	0.0	2.0	0.0	0.0	3.8	1.7	0.6
IXHL Incannex Healthcare	0.2141 of 5 stars	0.0	2.0	0.0	0.0	2.4	0.8	0.0
VIVS VivoSim Labs	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
AIMD Ainos	N/A	N/A	N/A
ATNF 180 Life Sciences	N/A	N/A	N/A
IXHL Incannex Healthcare	N/A	N/A	N/A
VIVS VivoSim Labs	N/A	N/A	N/A

Latest VIVS, AIMD, IXHL, and ATNF Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/14/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
7/29/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
7/12/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/27/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/11/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)

(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AIMD Ainos	$20K	890.06	N/A	N/A	$2.46 per share	1.55
ATNF 180 Life Sciences	N/A	N/A	N/A	N/A	$2.91 per share	N/A
IXHL Incannex Healthcare	$10K	1,939.44	N/A	N/A	$0.18 per share	3.66
VIVS VivoSim Labs	$140K	45.31	N/A	N/A	$3.67 per share	0.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AIMD Ainos	-$14.86M	-$4.99	N/A	∞	N/A	N/A	-108.25%	-56.94%	11/4/2025 (Estimated)
ATNF 180 Life Sciences	-$6.17M	-$15.07	N/A	∞	N/A	N/A	-141.25%	-80.77%	11/12/2025 (Estimated)
IXHL Incannex Healthcare	-$18.46M	-$1.21	N/A	∞	N/A	N/A	-342.92%	-148.64%	9/29/2025 (Estimated)
VIVS VivoSim Labs	-$2.48M	-$10.20	N/A	∞	N/A	-1,396.48%	-32.95%	-21.31%	N/A

Latest VIVS, AIMD, IXHL, and ATNF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	AIMD Ainos	N/A	-$0.99	N/A	-$0.99	N/A	N/A
8/12/2025	Q1 2026	VIVS VivoSim Labs	N/A	-$1.14	N/A	-$1.14	N/A	$0.04 million
7/23/2025	Q2 2025	ATNF 180 Life Sciences	N/A	-$0.30	N/A	-$0.30	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AIMD Ainos	N/A	N/A	N/A	N/A	N/A
ATNF 180 Life Sciences	N/A	N/A	N/A	N/A	N/A
IXHL Incannex Healthcare	N/A	N/A	N/A	N/A	N/A
VIVS VivoSim Labs	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AIMD Ainos	0.96	2.88	2.61
ATNF 180 Life Sciences	N/A	0.58	0.58
IXHL Incannex Healthcare	N/A	2.12	2.12
VIVS VivoSim Labs	N/A	4.52	4.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AIMD Ainos	N/A
ATNF 180 Life Sciences	4.07%
IXHL Incannex Healthcare	0.43%
VIVS VivoSim Labs	8.23%

Insider Ownership

Company	Insider Ownership
AIMD Ainos	10.39%
ATNF 180 Life Sciences	38.20%
IXHL Incannex Healthcare	15.49%
VIVS VivoSim Labs	3.72%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AIMD Ainos	40	4.66 million	4.17 million	Not Optionable
ATNF 180 Life Sciences	7	6.04 million	3.73 million	No Data
IXHL Incannex Healthcare	3	29.43 million	24.88 million	Not Optionable
VIVS VivoSim Labs	20	2.60 million	2.50 million	N/A

VIVS, AIMD, IXHL, and ATNF Headlines

Recent News About These Companies

VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

August 14, 2025 | finanznachrichten.de

VivoSim appoints Lialin as Chief Commercial Officer

August 14, 2025 | msn.com

VivoSim Labs, Inc. Appoints Tony Lialin as Chief Commercial Officer to Drive Growth in 3D Drug Testing Services

August 14, 2025 | quiverquant.comQ

VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

August 14, 2025 | financialpost.comF

VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

August 14, 2025 | globenewswire.com

VivoSim: Fiscal Q1 Earnings Snapshot

August 12, 2025 | timesunion.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIVS, AIMD, IXHL, and ATNF Company Descriptions

Ainos NASDAQ:AIMD

$3.82 -0.16 (-4.02%)

As of 08/29/2025 04:00 PM Eastern

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

180 Life Sciences NASDAQ:ATNF

$2.87 -0.11 (-3.69%)

As of 08/28/2025

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

Incannex Healthcare NASDAQ:IXHL

$0.66 +0.04 (+6.63%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$0.66 0.00 (-0.15%)

As of 08/29/2025 07:59 PM Eastern

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

VivoSim Labs NASDAQ:VIVS

$2.44 +0.57 (+30.48%)

As of 08/29/2025 04:00 PM Eastern

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time